Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity

NCT: NCT07838649 · NOT_YET_RECRUITING

NCT IDNCT07838649
StatusNOT_YET_RECRUITING
Start Date2026-11-01
Completion2029-12-12
SponsorWashington University School of Medicine (OTHER)
First posted
Last updated

Brief Summary

This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or lymphoma undergoing treatment with anthracycline for cancer therapy.

Frequently Asked Questions

What is Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity?

Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity is a clinical trial registered under NCT07838649. Current status: NOT_YET_RECRUITING.

What is the status of NCT07838649?

The current status of NCT07838649 (Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity) is: NOT_YET_RECRUITING.

When did Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity start?

Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity started on 2026-11-01.

Related Devices

PMA P230014Fluorescence imaging for breast cancer detectionLumicell, Inc. PMA P250008OCT imaging system with AI/ML software for adjunctive detection of breast cancerPerimeter Medical Imaging Ai, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑